Detalhe da pesquisa
1.
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 22(5): 678-689, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33848462
2.
A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma.
Cancer Chemother Pharmacol
; 89(6): 825-831, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35322287